Dachaigh › Aillse a' bhroilleach › Nebraska › Omaha
Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Omaha, NE
Tha 22 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann agus timcheall air Omaha (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A’ fastadhÌre 3
- Nebraska Cancer Specialists, Omaha
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A’ fastadhÌre 3
- Nebraska Cancer Specialists, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
A’ fastadhÌre 3
- Research Site, Omaha
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
A’ fastadhÌre 2
- Nebraska Cancer Specialists, Omaha
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
A’ fastadhÌre 2
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A’ fastadhÌre 3
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
A’ fastadhÌre 1/2
- Nebraska Cancer Specialists, Omaha
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A’ fastadhÌre 3
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
- University of Nebraska Medical Center, Omaha
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A’ fastadhÌre 3
- Nebraska Cancer Specialists, Omaha
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A’ fastadhÌre 3
- Nebraska Cancer Specialists, Omaha
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
A’ fastadhÌre 3
- Nebraska Medicine-Village Pointe, Omaha
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- agus 3 a bharrachd
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
A’ fastadhÌre 1
- Nebraska Cancer Specialists, Omaha
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A’ fastadhÌre 3
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
A’ fastadhÌre 2
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Integrated Cancer Repository for Cancer Research
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- agus 1 a bharrachd
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A’ fastadhÌre 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
ERAS Protocols in Breast Conserving Surgery
A’ fastadh
- University of Nebraska Medical Center, Omaha
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A’ fastadhÌre 3
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mìle air falbh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Omaha
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
A’ fastadhÌre 1
- Biotheryx Investigative Site, Omaha
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A’ fastadhSgrùdadh amharc
- Nebraska Methodist, Omaha
Sgrùdaidhean Aillse a' bhroilleach ann am bailtean eile
- New York City, NY136 sgrùdaidhean
- Houston, TX126 sgrùdaidhean
- Boston, MA112 sgrùdaidhean
- Nashville, TN81 sgrùdaidhean
- Los Angeles, CA73 sgrùdaidhean
- Edison, NJ68 sgrùdaidhean
- St. Louis, MO64 sgrùdaidhean
- Queens, NY64 sgrùdaidhean
- Durham, NC64 sgrùdaidhean
- Chicago, IL59 sgrùdaidhean
- Philadelphia, PA56 sgrùdaidhean
- Dallas, TX55 sgrùdaidhean
Sgrùdaidhean eile ann an Omaha
- Aillse Prostata27 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag24 sgrùdaidhean
- Aillse (gach seòrsa)18 sgrùdaidhean
- Aillse colorectal18 sgrùdaidhean
- Myeloma iomaill16 sgrùdaidhean
- Cancer Ovarian14 sgrùdaidhean
- Liomfoma Neo-Hodgkin14 sgrùdaidhean
- Cancer Pancreatic14 sgrùdaidhean
- Ailse metastatach13 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil13 sgrùdaidhean
- Fàilligeadh a' Chridhe13 sgrùdaidhean
- Melanoma12 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.